These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 25800976)

  • 1. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight.
    Aprile G; Ongaro E; Del Re M; Lutrino SE; Bonotto M; Ferrari L; Rihawi K; Cardellino GG; Pella N; Danesi R; Fasola G
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):165-78. PubMed ID: 25800976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment.
    Barzi A; Thara E
    Expert Opin Biol Ther; 2014 Sep; 14(9):1319-32. PubMed ID: 24881691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
    Javle M; Smyth EC; Chau I
    Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic agent ramucirumab: meaningful or marginal?
    Wadhwa R; Elimova E; Shiozaki H; Sudo K; Blum MA; Estrella JS; Chen Q; Song S; Ajani JA
    Expert Rev Anticancer Ther; 2014 Apr; 14(4):367-79. PubMed ID: 24605771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
    Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
    Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting HER 2 and angiogenesis in gastric cancer.
    Jomrich G; Schoppmann SF
    Expert Rev Anticancer Ther; 2016; 16(1):111-22. PubMed ID: 26567753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of ramucirumab in gastroesophageal adenocarcinoma.
    Elimova E; Lin Q; Song S; Ajani JA
    Future Oncol; 2017 Aug; 13(18):1585-1592. PubMed ID: 28436242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic Therapy in Gastroesophageal Cancer.
    Jin Z; Yoon HH
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):499-510. PubMed ID: 28501090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.
    Chen LT; Oh DY; Ryu MH; Yeh KH; Yeo W; Carlesi R; Cheng R; Kim J; Orlando M; Kang YK
    Cancer Res Treat; 2017 Oct; 49(4):851-868. PubMed ID: 28052652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
    Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
    Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
    Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targetting esophageal and gastric cancers with monoclonal antibodies.
    Norguet E; Dahan L; Seitz JF
    Curr Top Med Chem; 2012; 12(15):1678-82. PubMed ID: 22978338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiogenesis targeting in gastro-intestinal cancers].
    Meric JB
    Bull Cancer; 2007; 94(7 Suppl):F207-15. PubMed ID: 17964998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
    Garrido M
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
    Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
    Saeed A; Park R; Sun W
    J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramucirumab and its use in gastric cancer treatment.
    Bronte G; Galvano A; Cicero G; Passiglia F; Rolfo C; Bazan V; Russo A
    Drugs Today (Barc); 2014 Sep; 50(9):613-21. PubMed ID: 25313368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab: a novel antiangiogenic agent.
    Wadhwa R; Taketa T; Sudo K; Blum-Murphy M; Ajani JA
    Future Oncol; 2013 Jun; 9(6):789-95. PubMed ID: 23718298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis inhibitors in early development for gastric cancer.
    Pinto MP; Owen GI; Retamal I; Garrido M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1007-1017. PubMed ID: 28770623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab: A Review in Advanced Gastric Cancer.
    Greig SL; Keating GM
    BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.